William Blair research analyst Myles Minter was quoted by MedCity News in its coverage of Moderna’s approvals for a vaccine that provides combined coverage against COVID-19 and the flu and its impact for investors.
“The key question for us is how much of the flu vaccination market Moderna can now capture with a combination vaccine,” Minter’s note to investors that was cited by the publication said.